NVCTNuvectis Pharma, Inc.
What is the market doing?
No clear lean: rangebound and heavily shorted.
Choppy, but holding above its 200-day average. Price is +39% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NVCT is trading
Nuvectis Pharma, Inc. is +238% over the past year while the S&P 500 is +16%: 222 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +39%
vs 200-day average · a clear uptrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 30%
Below its 52-week high
Details›
- Last close2026-10-23
- $20.01
- 1 monthS&P 500 −0.94%
- −7.6%
- 1 yearS&P 500 +16%
- +238%
- vs 50-day average$21.71
- −7.9%
- 52-week high
- $28.52
- 52-week low
- $5.65
- Annualised volatility
- 90%
| Year | Return |
|---|---|
| 2026 (year to date) | +165% |
| 2025 | +40% |
| 2024 | −35% |
| 2023 | +11% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +13% |
| Feb | 4 | 3 of 4 | +15% |
| Mar | 5 | 3 of 5 | +7.8% |
| Apr | 5 | 4 of 5 | +5.6% |
| May | 5 | 4 of 5 | +19% |
| Jun | 5 | 1 of 5 | +5.2% |
| Jul | 5 | 2 of 5 | −4.4% |
| Aug | 5 | 3 of 5 | +0.63% |
| Sep | 5 | 0 of 5 | −9.4% |
| Oct | 5 | 2 of 5 | −2.1% |
| Nov | 4 | 1 of 4 | −9.0% |
| Dec | 4 | 3 of 4 | +7.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.